Abstract：Objective To systematically evaluate the efficacy and safety of steroid combined with immunosuppressants in the treatment of primary IgA nephropathy in children. Methods English and Chinese electronic databases were searched to include the studies on the efficacy and safety of steroid combined with immunosuppressants versus steroid alone in the treatment of primary IgA nephropathy in children. Outcome measures included proteinuria remission rate, urinary protein quantification, incidence of adverse events, estimated glomerular filtration rate, and incidence of renal dysfunction. Review Manager 5.3 software was used for data analysis. Results A total of 7 studies with 381 children were included. The children had moderate to severe proteinuria. The Meta analysis showed that compared with the steroid alone group, the steroid combined with immunosuppressants group achieved a significantly higher rate of proteinuria remission (RR=1.36, 95% CI: 1.19-1.55, P < 0.001) and significantly lower urinary protein quantification (SMD=-0.82, 95% CI: -1.23 to -0.41, P < 0.001). There was no significant difference in the incidence rate of adverse events between the two groups (RR=1.28, 95% CI: 0.92-1.77, P=0.14). Conclusions The current evidence shows that for children with primary IgA nephropathy who have moderate to severe proteinuria, steroid combined with immunosuppressants has a better effect than steroid alone and does not increase the incidence rate of adverse events.
ZHOU Jian-Mei,ZHONG Xu-Hui,SHI Xin-Miao et al. Efficacy and safety of steroid combined with immunosuppressants in the treatment of primary IgA nephropathy in children: a Meta analysis[J]. CJCP, 2020, 22(8): 860-866.
Jiang M, Xiao Z, Rong L, et al. Twenty-eight-year review of childhood renal diseases from renal biopsy data:a single centre in China[J]. Nephrology (Carlton), 2016, 21(12):1003-1009.
[2]
Santangelo L, Netti GS, Giordano P, et al. Indications and results of renal biopsy in children:a 36-year experience[J]. World J Pediatr, 2018, 14(2):127-133.
[3]
Nie S, He W, Huang T, et al. The spectrum of biopsy-proven glomerular diseases among children in China:a national, cross-sectional survey[J]. Clin J Am Soc Nephrol, 2018, 13(7):1047-1054.
[4]
Wyatt RJ, Kritchevsky SB, Woodford SY, et al. IgA nephropathy:long-term prognosis for pediatric patients[J]. J Pediatr, 1995, 127(6):913-919.
Oremus M, Wolfson C, Perrault A, et al. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials[J]. Dement Geriatr Cogn Disord, 2001, 12(3):232-236.
[9]
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9):603-605.
Yoshikawa N, Honda M, Iijima K, et al. Steroid treatment for severe childhood IgA nephropathy:a randomized, controlled trial[J]. Clin J Am Soc Nephrol, 2006, 1(3):511-517.
[16]
Kawasaki Y, Hosoya M, Suzuki J, et al. Efficacy of multidrug therapy combined with mizoribine in children with diffuse IgA nephropathy in comparison with multidrug therapy without mizoribine and with methylprednisolone pulse therapy[J]. Am J Nephrol, 2004, 24(6):576-581.
[17]
Uzu T, Harada T, Ko M, et al. Effect of corticosteroid therapy on the progression of IgA nephropathy with moderate proteinuria[J]. Clin Exp Nephrol, 2003, 7(3):210-214.
[18]
Coppo R, Peruzzi L, Amore A, et al. IgACE:a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria[J]. J Am Soc Nephrol, 2007, 18(6):1880-1888.
[19]
Song YH, Cai GY, Xiao YF, et al. Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy:a meta-analysis[J]. BMC Nephrol, 2017, 18(1):61.
[20]
Du B, Jia Y, Zhou W, et al. Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy:an update meta-analysis[J]. BMC Nephrol, 2017, 18(1):245.
[21]
Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy[J]. J Am Soc Nephrol, 2010, 21(10):1783-1790.
[22]
Floege J, Eitner F. Current therapy for IgA nephropathy[J]. J Am Soc Nephrol, 2011, 22(10):1785-1794.
[23]
Kiryluk K, Novak J, Gharavi AG. Pathogenesis of immunoglobulin A nephropathy:recent insight from genetic studies[J]. Annu Rev Med, 2013, 64:339-356.
